Safety, tolerability, pharmacokinetics, and efficacy of SHR-A1811, an antibody- drug conjugate, in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC): a multicenter, open-label, phase 1/2 study

被引：2
|
作者：
Lu, Shun
Jian, Hong
Hong, Wei
Song, Zhengbo
Yang, Nong
Hu, Sheng
Liang, Zibin
Wang, Yongsheng
Wang, Yan
Peng, Min
Yu, Yan
Li, You
Shuang, Jiapeng
Zhao, Kaijing
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT204
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT204
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Efficacy and Safety Data From a Phase 1/2 Trial of Tislelizumab in Chinese Patients With Non-Small Cell Lung Cancer (NSCLC)
    Zhou, Q.
    Zhao, J.
    Wang, J.
    Zhang, Q.
    Pan, H.
    Shen, L.
    Yuan, Y.
    Bai, Y.
    Liu, T.
    Gao, Y.
    Li, Y.
    Zhang, J.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S48 - S49
  • [42] An Open-Label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC)
    Tamura, Tomohide
    Nishio, Makoto
    Yamamoto, Nobuyuki
    Ohe, Yuichiro
    Wolff, Katharina
    Tsujimoto, Mika
    Enatsu, Sotaro
    Nakagawa, Kazuhiko
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S664 - S665
  • [43] Efficacy and safety of ensartinib in ALK-positive non-small cell lung cancer patients with brain metastases: A multicenter, open-label, single-arm, phase II study
    Chang, J.
    Wu, X.
    Guo, L.
    Zhang, T.
    Fu, C.
    Huang, S.
    Jiang, G.
    ANNALS OF ONCOLOGY, 2023, 34
  • [44] Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study
    Felip, Enriqueta
    de Braud, Filippo G.
    Maur, Michela
    Loong, Herbert H.
    Shaw, Alice Tsang
    Vansteenkiste, Johan F.
    John, Thomas
    Liu, Geoffrey
    Lolkema, Martijn P.
    Selvaggi, Giovanni
    Giannone, Vanessa
    Cazorla, Pilar
    Baum, Jason
    Balbin, O. Alejandro
    Wang, Luojun
    Lau, Yvonne Y.
    Scott, Jeffrey W.
    Tan, Daniel Shao-Weng
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (03) : 392 - 403
  • [45] A Phase 1b/2, Open-Label Study of Bintrafusp Alfa with Chemotherapy in Patients with Stage IV Non-Small Cell Lung Cancer
    Barlesi, F.
    Hiret, S.
    Rolfo, C.
    Grenga, I.
    Koenig, A.
    Vugmeyster, Y.
    Horn, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S27 - S27
  • [46] Exposure-response (ER) analyses of efficacy and safety of trastuzumab deruxtecan (T-DXd) to inform dosing recommendation in HER2-mutant non-small cell lung cancer (NSCLC)
    Khatri, Amit
    Polhamus, Daniel
    Cobbina, Enoch
    Garcia, Ramon
    Yoder, Todd
    Abutarif, Malaz
    Garimella, Tushar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] AN OPEN-LABEL PHASE II STUDY OF THE HSP90 INHIBITOR GANETESPIB (STA-9090) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Socinski, Mark A.
    Koczywas, Marianna
    Goldman, Jonathan
    Paschold, Eugene
    Horn, Leora
    Lufkin, Joelle
    Blackman, Ronald K.
    Teofilovici, Florentina
    Shapiro, Geoffrey
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S467 - S468
  • [48] Preliminary results of ENCORE 601, a phase 1 b/2, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)
    Johnson, Melissa Lynne
    Adjei, Alex A.
    Ramalingam, Suresh S.
    Janne, Pasi A.
    Dominguez, George
    Gabrilovich, Dmitry
    Deleon, Laura
    Hasapidis, Jeannette Lynne
    Diede, Scott J.
    Ordentlich, Peter
    Hellmann, Matthew David
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] Efficacy and safety of endostatin in combination with chemotherapy in small cell lung cancer: a phase 2 single-arm multicenter open-label trial
    Zhao, Yi
    Zhang, Xu
    Jin, Chenxing
    Yu, Xiaomin
    Zhang, Min
    Cao, Yang
    Li, Ying
    Wang, Aman
    Shan, Xiu
    Zhang, Jia
    Wang, Juhong
    Yin, Liu
    Tan, Xiaoxin
    Liu, Jiwei
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (03) : 3277 - 3285
  • [50] Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC)
    Ardizzoni, Andrea
    Razis, Evangelia
    Lichinitser, Mikhail
    Yilmaz, Ugur
    Grigorescu, Alexandru C.
    Morero, Jose Luis
    Skrickova, Jana
    Cervantes, Guadalupe
    Gottfried, Maya
    Van Meerbeeck, Jan
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S342 - S342
12345